Back to catalog
LibidoHigh evidence

PT-141

Melanocortin receptor agonist (bremelanotide) used for hypoactive sexual desire via central pathways rather than vascular mechanisms alone.

Half-life
~2.7 hours
Administration
Subcutaneous (branded clinical product exists)
Primary uses
HSDD (approved contexts) · Desire/arousal research

Mechanism

Activates melanocortin receptors in the CNS involved in sexual desire and arousal signaling.

  • HSDD (approved contexts)
  • Desire/arousal research

Dosing ranges

Educational ranges only — not medical advice. Confirm protocols with a qualified clinician.

Use caseTypical rangeFrequencyNotes
Clinical HSDD labeling (reference)1.75 mgAs needed, max dosing limits applyFollow approved product labeling and clinician direction

Clinical evidence

High evidence
Obstet Gynecol · 2019

Bremelanotide for hypoactive sexual desire disorder

Statistically significant improvements in desire scores vs placebo in premenopausal women.

Cautions

  • Nausea is the most common adverse event
  • Transient blood-pressure increases possible
  • Use only under appropriate clinical guidance where indicated

Provider comparison

Affiliate-style comparison cards for clinics, telehealth, and research suppliers. Verify licensing and product quality before purchasing.

Fountain Health
telehealth
4.7
From $249/mo

Licensed clinician consult + ongoing titration support

Compare offer
PeakRx Clinic
clinic
4.5
From $189/mo

In-person labs available in select metros

Compare offer
Research Supply Co.
research
4.1
Vial pricing

Research-only sourcing — not for human consumption labeling

View listing